All In Biotech

Drug Trial Radar · NCT07336641

LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice

LANDSCAPE - Demographic Characteristics and Treatment Profiles of Patients Affected by Inflammatory Skin Diseases (Psoriasis, Atopic Dermatitis, Alopecia Areata, Vitiligo, Hidradenitis Suppurativa) in Italian Clinical Practice

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20,000

Planned (sponsor's estimate)

Start

Jan 2026

Primary completion

May 2026

Study completion Jan 2028

Sponsor

Lead sponsor
Fondazione ISIDEAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12 years and older with psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.

Conditions

  • Psoriasis
  • Atopic Dermatitis
  • Vitiligo
  • Alopecia Areata
  • Hidradenitis Suppurativa

Interventions

  • Conventional Systemic TherapiesDrug

    Retrospective observation of conventional systemic treatments prescribed in routine clinical practice, including but not limited to methotrexate, cyclosporine, acitretin, and other conventional agents. No drugs are administered as part of this study; treatment data are collected from existing medical records.

  • Biologic TherapiesDrug

    Retrospective observation of biologic treatments prescribed in routine clinical practice, including but not limited to TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-4/IL-13 inhibitors, and JAK inhibitors. No drugs are administered as part of this study; treatment data are collected from existing medical records.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient Distribution by Disease TypeTime frame: January 2016 to December 2025
  2. Age at Treatment InitiationTime frame: January 2016 to December 2025
  3. Sex DistributionTime frame: January 2016 to December 2025

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • IRCCS Istituto Clinico Humanitas - Dermatology Unit

    Rozzano, Lombardy, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.